EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Amicus Therapeutics's Enterprise Value is $3,322.4 Mil.
Amicus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-100.0 Mil. Therefore, Amicus Therapeutics's EV-to-EBIT for today is -33.24.
The historical rank and industry rank for Amicus Therapeutics's EV-to-EBIT or its related term are showing as below:
FOLD'
s EV-to-EBIT Range Over the Past 10 Years
Min: -42.99 Med: -7.1 Max: -0.43
Current: -33.24
During the past 13 years, the highest EV-to-EBIT of Amicus Therapeutics was -0.43. The lowest was -42.99. And the median was -7.10.
FOLD's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs FOLD: -33.24
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Amicus Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $4,325.0 Mil.
Amicus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-100.0 Mil. Amicus Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.31%.
Amicus Therapeutics EV-to-EBIT Historical Data
The historical data trend for Amicus Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amicus Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, Amicus Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amicus Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's EV-to-EBIT falls into.
Amicus Therapeutics EV-to-EBIT Calculation
Amicus Therapeutics's EV-to-EBIT for today is calculated as:
Amicus Therapeutics's current Enterprise Value is $3,322.4 Mil.
Amicus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Amicus Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $4,325.0 Mil.
Amicus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-100.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics (Amicus Therapeutics) Business Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 